MISGAV, Israel, April 20, 2015 /PRNewswire/ --Endobetix Ltd., a developer of a minimally invasive, nonsurgical implant for the treatment of type 2 diabetes and obesity and a portfolio company of The Trendlines Group, announced today it has been selected as a finalist for Red Herring’s Top 100 Europe award, a prestigious list honoring the year’s most promising private technology ventures from the European business region.
Help employers find you! Check out all the jobs and post your resume.
